Soleno Therapeutics Set To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1, 2024

6/4/24 8:26:17 AM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $SLNO alert in real time by email

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

Get the next $SLNO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SLNO

Date	Price Target	Rating	Analyst
9/3/2024	$70.00	Buy	H.C. Wainwright
5/10/2024	$72.00	Outperform	Robert W. Baird
2/5/2024	$93.00	Overweight	Piper Sandler
1/23/2024	$63.00	Buy	Stifel
11/21/2023	$40.00	Buy	Guggenheim

More analyst ratings

$SLNO
Market Insights

Live Market Insights

Soleno Therapeutics Submits NDA To The U.S. FDA For DCCR (Diazoxide Choline) Extended-Release Tablets For The Treatment Of Prader-Willi Syndrome
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
6/28/24 8:02:36 AM ET
$SLNO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Soleno Therapeutics Set To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1, 2024
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
6/4/24 8:26:17 AM ET
$SLNO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. The chipmaker giant has seen an astounding 186% surge since the end of May 2023, fueled by skyrocketing demand for chips in artificial intelligence development. Veteran Wall Street investor Ed Yardeni recently coined “Magnificent One” to differentiate Nvidia’s extraordinary performance from the Magnificent Seven. To illustrate the magnitude of Nvidia's market value increase, just a year ago, the company was valued at $1 trillion. Today, it boasts a staggering $2.8 trillion valuation, making it the third-largest company in the U.S. Nvidia’s curren
5/29/24 5:56:11 PM ET
$ANF
$AVGO
$CVNA
$LLY
Clothing/Shoe/Accessory Stores
Consumer Discretionary
Semiconductors
Technology

$SLNO
Leadership Updates

Live Leadership Updates

Soleno Therapeutics Set to Join Russell 3000® Index
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta
6/4/24 8:00:00 AM ET
$SLNO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone
1/24/24 8:00:00 AM ET
$SLNO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors
REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience. "Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board," said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. "His impressive track record, including in rare diseases, will b
8/16/23 8:00:00 AM ET
$SLNO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. Details of the oral presentations are as follows: ESPE 2024 Title:Relaxation of Food Control Parameters Based on Improvements in the Food Safe Zone Questionnaire Occurs with Reduction of Hyperphagia in C
11/14/24 4:05:00 PM ET
$SLNO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Corporate Highlights New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) accepted by the U.S. Food and Drug Administration (FDA) and granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024. The FDA Review
11/6/24 4:05:00 PM ET
$SLNO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Soleno Therapeutics to Participate in Upcoming November Investor Conferences
REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET Event: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024Time: 8:00 AM GT A live audio webcast and replay of the Guggenheim and Jefferies events will be availab
10/28/24 8:00:00 AM ET
$SLNO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Soleno Therapeutics Set To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1, 2024

Chat with this insight

Recent Analyst Ratings for $SLNO

$SLNO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Yen Kristen sold $153,627 worth of shares (3,108 units at $49.43), decreasing direct ownership by 4% to 81,465 units (SEC Form 4)

CHIEF FINANCIAL OFFICER Mackaness James H sold $399,241 worth of shares (8,077 units at $49.43), decreasing direct ownership by 6% to 119,172 units (SEC Form 4)

Officer Hirano Patricia C sold $153,627 worth of shares (3,108 units at $49.43), decreasing direct ownership by 3% to 108,932 units (SEC Form 4)

$SLNO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

$SLNO Market Insights

Live Market Insights

Soleno Therapeutics Submits NDA To The U.S. FDA For DCCR (Diazoxide Choline) Extended-Release Tablets For The Treatment Of Prader-Willi Syndrome